PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Ashutosh Jaiswal

Medanta The Medicity

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 5, 2026 · JOURNAL ARTICLE

Real-world outcomes and immune-related adverse events with PD-1/ PD-L1 inhibitors in metastatic renal cell carcinoma: A prospective observational study

Asian Journal of Oncology

Single-center prospective observational study with modest sample size (n=31) and surrogate endpoint (ORR at 3 months); demonstrates feasibility in a LMIC setting but lacks a comparator and control group, and requires confirmation in larger studies.

PreliminarySajjan Rajpurohit Bladder and Urothelial Cancer Treatments Deni Gupta

Reported

Objective response rate (3 months)51.6%

Complete response2

Partial response14

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support